A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme

ClinicalTrials.gov ID: NCT01268566

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT01268566. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 12, 2026, 1:53 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of MEDI-575 in Adult Subjects With Recurrent Glioblastoma Multiforme

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The primary objective of this Phase II study is to evaluate the progression-free survival at 6 months in adult subjects with a first recurrence of Glioblastoma Multiforme who are treated with MEDI-575.

Study identification

NCT ID: NCT01268566
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: MedImmune LLC; Industry
Enrollment: 62 participants

Conditions and interventions

Conditions

Glioblastoma Multiforme

Interventions

MEDI-575 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 95 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 2011 (Type not available)
Primary completion: Nov 2012 (Actual)
Completion: Nov 2012 (Actual)
Last update posted: Apr 6, 2017

2011 – 2012

United States locations

U.S. sites: 12
U.S. states: 11
U.S. cities: 12

Facility	City	State	ZIP	Site status
Research Site	Tucson	Arizona	—	—
Research Site	Los Angeles	California	—	—
Research Site	Stanford	California	—	—
Research Site	Chicago	Illinois	—	—
Research Site	Boston	Massachusetts	—	—
Research Site	Detroit	Michigan	—	—
Research Site	New York	New York	—	—
Research Site	Canton	Ohio	—	—
Research Site	Pittsburgh	Pennsylvania	—	—
Research Site	Nashville	Tennessee	—	—
Research Site	San Antonio	Texas	—	—
Research Site	Seattle	Washington	—	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT01268566, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 6, 2017 · Synced Nov 12, 2026